A comparative analysis of the phase III ASCENT-03 and TROPION-Breast02 trials reports that TROP2-targeting antibody–drug conjugates consistently improved progression-free survival over standard chemotherapy in first-line metastatic triple-negative breast cancer for patients ineligible for immunotherapy. The dataset aligns across trial designs, supporting a stronger efficacy signal for TROP2-directed ADC strategies in this treatment setting.
Get the Daily Brief